Sparlon Risk Management Plan For Serious Skin Reactions To Be Discussed By Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
During review, FDA staff disagrees about significance and implications of serious skin reactions and other adverse events with Sparlon.
You may also be interested in...
Cephalon Sparlon Additional Pre-Approval Safety Study Recommended To Assess Skin Reaction Risk
FDA’s Psychopharmacologic Drugs Advisory Committee rules safety for modafinil product in children with attention deficit/hyperactivity disorder has not been adequately demonstrated.
Cephalon Sparlon Additional Pre-Approval Safety Study Recommended To Assess Skin Reaction Risk
FDA’s Psychopharmacologic Drugs Advisory Committee rules safety for modafinil product in children with attention deficit/hyperactivity disorder has not been adequately demonstrated.
ADHD Black Box Warning On Psychiatric/Cardiac Events Is Unnecessary, Pediatric Committee Says
FDA’s Pediatric Advisory Committee recommends adding regular warnings on possible psychosis, aggression, and cardiovascular risks to all attention deficit/hyperactivity disorder drugs.